| Darrell R. Abernethy | |
| Birth Date: | November 2, 1949 |
| Field: | Pharmacology |
| Work Institutions: | Johns Hopkins School of Medicine |
| Alma Mater: | University of Kansas School of Medicine |
Darrell R. Abernethy (1949–2017) was an American associate director for drug safety in the Office of Clinical Pharmacology at the Food and Drug Administration.[1]
Abernethy received a M.D. and Ph.D. for pharmacology at the University of Kansas School of Medicine in 1976.[2] [3] He then continued his clinical training in internal medicine at Jackson Memorial Hospital and the University of Miami through board certification and followed with post-doctoral fellowship training for clinical pharmacology at the Massachusetts General Hospital. In 1981, Abernethy became the assistant professor of psychiatry and medicine at Tufts University School of Medicine. In 1983, he moved to Baylor College of Medicine and advanced as an associate professor of medicine in the division of hypertension and clinical pharmacology. He then moved to Brown University School of Medicine in 1986 as the chief of the division of clinical pharmacology, and later was promoted as the professor of medicine. He was the former Francis Cabell Brown Professor and the director of the division of clinical pharmacology at Georgetown University School of Medicine from 1994 to 1999. He then became the chief of the laboratory of clinical investigation at the National Institute on Aging until 2007.[3] [4] Abernethy died on Nov 18, 2017 from advanced pancreatic cancer.[5]
Abernethy contributed to understanding of mechanisms of peripheral distribution for drugs and drug disposition and effect in obesity, the knowledge base in pharmacokinetic or pharmacodynamic relationships for cardiovascular drugs in aging. He improved the concept of aging with his research that the pathophysiology of aging must be considered interpreting the drug effects on aged patient. His last research was on the role of genetic polymorphisms of drug effectors with effective responses to cardiovascular drugs. Moreover, to better quantify the effects of multiple medications on functional performance in older adults, he was developing a Drug Burden Index.[1]